Emerald Health Therapeutics, Inc. (TSXV: EMH; OTCQX: EMHTF) is a Licensed Producer committed to creating new consumer experiences with recreational and wellness-oriented cannabis products. With an emphasis on innovation and production excellence, Emerald has built a platform of distinct operating assets designed to uniquely serve the Canadian marketplace and international opportunities.
Oct 29, 2020
Annual General and Special Meeting of Shareholders
Further details regarding the meeting will be included in the company’s information circular, which is expected to be mailed to shareholders in late September 2020.
Pure 41.3%-owned joint venture, Pure Sunfarms (PSF), is located in Delta, British Columbia. Its fully operational 1.1 million square foot facility is producing high quality, affordably priced products. The state-of-the-art hybrid greenhouse is one of the largest, lowest operating cost cannabis cultivation facilities in the world. PSF successfully launched its line of branded products into Ontario, British Columbia and Alberta and continues to focus on expanding its sales territories and brand presence as well as developing value-added oils and Cannabis 2.0 products.
Verdélite, Emerald’s wholly-owned 88,000 square feet indoor grow facility in Saint-Eustache, QC, is a Licensed Producer and has a Standard Processing license, allowing it to not only cultivate and sell cannabis flowers but package, extract, manufacture, synthesize, test and sell next-generation cannabis products. Verdélite is now licensed to sell and distribute packaged, branded dried cannabis products directly to provincial/territorial wholesalers and authorized private retailers.
Emerald’s Richmond operation has been designed for health and wellness-oriented organic cannabis cultivation and consists of a 78,000 sq. ft. purpose-built greenhouse facility. The facility received its organic certification and is now in full production while a second 78,000 sq. ft greenhouse is under construction. The organically grown products produced at this facility will play an integral role in the expansion of Emerald’s product line. They will be particularly focused on serving adult-use and medical consumers seeking health and wellness benefits.
Victoria, Emerald’s wholly-owned 10,000 square foot facility in Victoria, BC, includes a 2000 square foot indoor grow and a 6000 square foot packaging and extraction operation. Victoria is Emerald’s Medicinal Cannabis hub, where customer relations, packaging and distribution take place. Victoria’s R&D lab is focused on plant genetics, breeding and next generation cannabis products development.
Avalite, Emerald’s wholly-owned analytical testing laboratory, is a Licensed Dealer and authorized to import and export cannabis and cannabis oils for R&D, prepare any manipulation, formulation, dosage form, strength or package size of cannabis, including mixtures with other additives, controlled substances, and non-controlled substances – expanding possible research and product innovation opportunities.
Emerald Health Naturals, Emerald’s 51/49 joint venture with Emerald Health Bioceuticals has exclusive Canadian distribution rights of the award-winning Endo product line (PhytoCann® Complex) of non-cannabis endocannabinoid-supporting products that can be sold through natural health product channels. The unique branding opportunity introduce consumers to the benefits of endocannabinoid-supporting products with the Emerald name.
Emerald entered into a multi-year agreement with Valens GroWorks Corp. to contract cannabis extraction and white-label product development services. Under the Agreement, Emerald will supply Valens with a minimum of 10,000 kg of cannabis and hemp biomass annually for processing into premium quality resins and distillates using Valens’ extraction and processing methods. Valens will also provide white label services including formulation, mixing and filling for product formats such as vaporizers, softgels and tinctures.
Emerald Health Biotechnology Espana is a cannabis-industry-leading research organization which Emerald has contracted to elucidate the mechanism of action of proprietary formulations and dosage forms for product development. This collaboration can strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery and dosage.